Recombinant Human IFN-alpha G/IFNA5 Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 11017-IF

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
11017-IF-050
11017-IF-010
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

HEK293

Accession #

P01569.1

Conjugate

Unconjugated

Applications

Bioactivity

View all IFN-alpha G/IFNA5 Proteins and Enzymes »

Product Specifications

Source

Human embryonic kidney cell, HEK293-derived human IFN-alpha G/IFNA5 protein
Leu22-Glu189

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Leu22

Predicted Molecular Mass

20 kDa

SDS-PAGE

18-22 kDa, under reducing conditions.

Activity

Measured in anti-viral assays using HeLa human cervical epithelial carcinoma cells infected with encephalomyocarditis (EMC) virus. Meager, A. (1987) in Lymphokines and Interferons, a Practical Approach. Clemens, M.J. et al. (eds): IRL Press. 129.
The ED50 for this effect is 1.00-15.0 pg/mL.

Scientific Data Images for Recombinant Human IFN-alpha G/IFNA5 Protein, CF

Recombinant Human IFN-alpha G/IFNA5 Protein Bioactivity.

Recombinant Human IFN-alpha G/IFNA5 Protein (Catalog # 11017-IF) demonstrates anti-viral activity in HeLa human cervical epithelial carcinoma cells infected with encephalomyocarditis (EMC) virus. The ED50 for this effect is 1.00-15.0 pg/mL

Recombinant Human IFN-alpha G/IFNA5 Protein SDS-PAGE.

2 μg/lane of Recombinant Human IFN-alpha G/IFNA5 Protein (Catalog # 11017-IF) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 18-22 kDa.

Formulation, Preparation and Storage

11017-IF
Formulation Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution Reconstitute at 100 μg/mL in PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: IFN-alpha G/IFNA5

Interferons (IFN) are a family of cytokines with potent antiviral, antiproliferative and immunomodulatory properties, classified based on their binding specificity to cell surface receptors (1). Human IFNA2 was originally cloned in the early ‘80s and now more than a dozen closely related IFN alpha subtypes have been identified in both the human and mouse genome, each sharing about 80% amino acid (aa) sequence homology (2-4). Structurally, type I IFNs belong to the class of five helical‑bundle cytokines, with the IFNA subtypes containing 2 conserved disulfide bonds (5). The mature human IFNA5, also known as IFN-alpha G, shares 40% aa sequence identity with mouse IFNA5. The type I IFNs bind to the interferon alpha receptor (IFNAR), which consists of two subunits: IFNAR1 (alpha -subunit) and IFNAR2 (beta -subunit) (6, 7). Individual IFNA subtypes are known to display unique efficacies to viral protection, and IFNA5 has been shown to be an intermediate inducer of IFN‑stimulated genes and anti-viral protection (8). IFNA5 is the only IFNA subtype detected in normal liver and has been shown to induce stronger signaling and higher expression of antiviral genes than IFNA2 in hepatocytic cells (9). IFNA5 also exhibits strong antiviral effects against SARS‑CoV‑2 (10).

References

  1. Pestka, S. et al. (1987) Annu. Rev. Biochem. 56:727.
  2. Goeddel, D.V. et al. (1980) Nature 287:411.
  3. Matsumiya, T. et al. (2007) J. Immunol. 179:4542.
  4. Schreiber, G. and J. Piehler (2015) Trends Immunol. 36:139.
  5. Wittling, M.C. et al. (2021) Front Immunol. 11:605673.
  6. van Pesch, V. et al. (2004) J. Virol. 78:8219.
  7. James, C.M. et al. (2007) Vaccine. 25(10):1856.
  8. Moll, H.P. et al. (2011) Cytokine. 53:52.
  9. Larrea, E. et al. (2004) J Interferon Cytokine Res. 24:497.
  10. Schuhenn, J. et al. (2022) PNAS https://doi.org/10.1073/pnas.2111600119.

Long Name

Interferon alpha G

Alternate Names

Ifa5, IFNA5, IFNalpha G

Entrez Gene IDs

3442 (Human); 15968 (Mouse); 690894 (Rat)

Gene Symbol

IFNA5

UniProt

P01569.1

Additional IFN-alpha G/IFNA5 Products

Product Documents for Recombinant Human IFN-alpha G/IFNA5 Protein, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Recombinant Human IFN-alpha G/IFNA5 Protein, CF

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.